Overview

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

Status:
Not yet recruiting
Trial end date:
2025-01-30
Target enrollment:
Participant gender:
Summary
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals